Carisma Therapeutics

At Carisma we are focused on three principles of work to make engineered myeloid cell therapy a reality: • Testing and validating our foundational scientific perspective • Redefining manufacturing • Fueling, amplifying and extending our platform’s capabilities through thoughtful partnerships Register for our upcoming webcast to learn about how these principles are guiding our latest efforts to leverage the CAR-Macrophage platform: https://bit.ly/39dHRwm

Don’t miss Carisma Therapeutics President & Chief Executive Officer Steven Kelly fireside chat today at the 7th Annual Evercore HealthCONx Conference at 9:35 am ET. The webcast is available on the investor section of our website: https://lnkd.in/eyHna8cV

Happy Thanksgiving from Carisma Therapeutics! This Thanksgiving, we extend our heartfelt gratitude to all who support and inspire our mission to transform immunotherapy. Your trust drives us to innovate and strive for meaningful change in healthcare. May your day be filled with warmth, happiness, and cherished moments with loved ones. Wishing you and your families a joyous and memorable Thanksgiving! #Thanksgiving #Gratitude #Innovation #CarismaTherapeutics

Today we announced that President and CEO Steven Kelly will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on December 5 at 9:35 am ET. For full details and webcast information, read our press release: https://lnkd.in/gPWMqnDc

Today at American Association for the Study of Liver Diseases (AASLD), we shared exciting new preclinical results demonstrating the anti-fibrotic potential of engineered macrophages across multiple fibrosis models. These results underscore the efficacy of our engineered macrophages as a differentiated, off-the-shelf approach for treating advanced liver fibrosis. Read more in our press release: https://lnkd.in/eXFC4bwn #AASLD2024 #LiverFibrosis #CellTherapy #Biotech #Innovation

This #VeteransDay, we honor the brave men and women who have selflessly served in our armed forces. We are deeply grateful for your sacrifice and dedication to protecting our freedom. Thank you for your service. #VeteransDay2024 #ThankYouVeterans #CarismaHonors

Today, we shared new preclinical data on our anti-GPC3 in vivo CAR-M therapy for hepatocellular carcinoma (HCC), developed in collaboration with Moderna. This innovative therapy reprograms myeloid cells to precisely target and destroy GPC3+ tumor cells, showing immense potential as an off-the-shelf solution for solid tumors. Learn more: https://lnkd.in/eUCFJZz2 #Immunotherapy #CancerResearch #CellTherapy #HCC #SITC2024 #CarismaTherapeutics

Today, we shared our business update and financial results for the third quarter of 2024. For a full overview of our progress and financials, read the press release here: https://lnkd.in/e4rK_aFn #biotech #financialresults #Q32024 #CarismaTherapeutics #innovation

We’re excited to be part of #SITC2024 in Houston! On November 8, 2024, we will showcase our trial-in-progress poster for the Phase 1 study of anti-HER2 CAR-Monocytes targeting solid tumors. Looking forward to connecting with the vibrant immunotherapy community! #SITC2024 #Immunotherapy #CellTherapy #Oncology #Innovation #CancerResearch

We’re excited to be part of #SITC2024 in Houston! On November 8, 2024, we, together with Moderna, will present new preclinical efficacy data on our anti-GPC3 in vivo CAR-M therapy for hepatocellular carcinoma. Link: https://lnkd.in/exqVYjD7 Looking forward to connecting with the vibrant immunotherapy community! #SITC2024 #Immunotherapy #CellTherapy #Oncology #Innovation #CancerResearch